Proposed Section Structure
This topic is best organized around clinical need, implementation strategy, measured outcomes, and practice implications. A logical structure is: Highlights; Clinical Background and Unmet Need; Study Design and Quality-Improvement Framework; Intervention and Eligibility Algorithm; Key Results; Clinical Interpretation; Limitations and Generalizability; Practical Implications for Emergency and ENT Services; Conclusion; Funding, Registration, and Citation.
Highlights
Implementation of a clinical care guideline (CCG) for nebulized tranexamic acid (TXA) in post-tonsillectomy hemorrhage (PTH) was associated with rapid uptake in the emergency department, with order set use in 95.7% of treated patients.
Among patients presenting with PTH, the proportion requiring operative hemorrhage control fell from 50.0% before implementation to 27.1% after implementation, an absolute risk reduction of 0.320 (95% CI 0.116-0.500; p = 0.001).
The intervention targeted a clinically relevant subgroup: patients with active bleeding or visible clot who were stable enough to receive nebulized therapy and protect the airway.
The study is notable not only for the treatment effect signal, but for showing how guideline design, workflow integration, and standardized order sets can accelerate adoption of a new emergency ENT practice.
Clinical Background and Unmet Need
Post-tonsillectomy hemorrhage remains one of the most consequential complications after tonsillectomy. Although most patients do not experience clinically significant bleeding, those who return to the emergency department often present with substantial anxiety, variable bleeding severity, and a real risk of deterioration. Management can be especially challenging because hemorrhage may have slowed by the time of evaluation, only to recur later, and because ED teams must balance immediate hemostasis, airway safety, hydration, and otolaryngology consultation.
Historically, many patients with meaningful secondary PTH have been admitted for observation or taken to the operating room for hemorrhage control, especially when active bleeding persists or a fresh clot is present in the tonsillar fossa. Yet operative management carries its own burdens: anesthetic exposure, resource utilization, prolonged length of stay, and the risks associated with airway manipulation in a recently bleeding patient.
Tranexamic acid, an antifibrinolytic agent that inhibits plasminogen activation and stabilizes clot formation, has become increasingly familiar across multiple bleeding settings. In upper aerodigestive tract bleeding, nebulized delivery is attractive because it is noninvasive, can be administered quickly in the ED, and may provide local hemostatic benefit without immediate need for intravenous access or procedural intervention. Even so, moving from promising therapeutic concept to routine hospital practice is difficult. Staff turnover, varying awareness across specialties, and order-entry barriers can slow or fragment adoption. This is the implementation gap addressed by the present study.
Study Design and Quality-Improvement Framework
Lavin and colleagues evaluated whether a hospital-wide clinical care guideline could improve adherence to a nebulized TXA protocol for PTH and whether this implementation was associated with fewer operative interventions. The team used Model for Improvement methodology, a standard quality-improvement framework that emphasizes iterative testing, workflow reliability, and measurable outcomes.
The study compared data from two years before and two years after CCG initiation. This was therefore a pre-post implementation analysis rather than a randomized trial. The denominator populations were large: 2805 tonsillectomies in the pre-implementation period and 5382 in the post-implementation period. Emergency department returns for bleeding were then assessed across both periods.
The core intervention was a structured ED algorithm. Patients presenting with active bleeding or a visible blood clot after tonsillectomy were designated candidates for three nebulized TXA treatments. Exclusion criteria were severe bleeding, absence of active bleeding or clot, and inability to tolerate nebulization or protect the airway. Importantly, this reflects a clinically selective strategy rather than universal TXA use for every patient reporting postoperative bleeding.
An electronic order set was created to facilitate uptake, likely reducing variation in medication ordering and helping standardize recognition of appropriate candidates. The reported outcomes included ED returns for PTH, order set use, frequency of TXA administration, returns to the operating room for hemorrhage control, and secondary ED returns.
Intervention Pathway and Eligibility Logic
The protocol is clinically intuitive. In a patient with post-tonsillectomy bleeding, the first priority remains airway assessment and identification of severe hemorrhage. Those with brisk bleeding, hemodynamic instability, or inability to protect the airway were excluded from the nebulized TXA pathway and would appropriately proceed to more urgent otolaryngology and anesthetic management. By contrast, patients with active oozing or visible clot but without immediate airway compromise were treated with three nebulized TXA doses.
This distinction matters. It positions nebulized TXA not as a replacement for surgery in unstable patients, but as an early hemostatic measure for the common and operationally difficult middle group: patients who are bleeding enough to warrant concern, but not so unstable that they bypass bedside medical treatment. In practice, that is exactly the group in whom a standardized ED protocol could meaningfully reduce unnecessary operative escalation.
Key Results
Population and event rates
Patient age did not differ between the pre- and post-implementation cohorts, which reduces concern that age-related differences in bleeding severity or management thresholds explain the observed findings. ED return rates for bleeding were also similar: 70 of 2805 tonsillectomies (2.5%) before implementation and 155 of 5382 (2.9%) after implementation, with no statistically significant difference. This is an important anchor point because it suggests the intervention did not simply coincide with a lower-risk postoperative population.
Guideline adherence and operational uptake
Post-implementation, 126 patients met inclusion criteria for TXA, representing 81.3% of post-implementation ED bleeding presentations. Order set utilization among patients receiving TXA in the ED reached 95.7%, a strikingly high level of workflow adherence for a new protocol. From an implementation science perspective, this may be one of the study’s most impressive findings. It indicates that the CCG was not merely published or announced; it was integrated into practice in a durable, observable way.
Association with operative management
The headline clinical result was the reduction in operative PTH management. Before guideline implementation, 35 of 70 patients presenting with post-tonsillectomy bleeding required return to the operating room, or 50.0%. After implementation, this fell to 42 of 155 patients, or 27.1%. The difference was statistically significant (p = 0.001), with an absolute risk reduction of 0.320 and a 95% confidence interval of 0.116 to 0.500.
Clinically, this effect size is substantial. An absolute reduction of 32 percentage points suggests that for a meaningful proportion of otherwise operative patients, standardized nebulized TXA-based management may have stabilized bleeding sufficiently to avoid surgery. Put differently, the number needed to treat, estimated from the absolute risk reduction, would be roughly 3.1. Because this is derived from a nonrandomized pre-post comparison, it should be interpreted cautiously, but the magnitude is difficult to ignore.
Secondary outcomes
The abstract indicates that secondary ED returns were measured, though specific numerical results are not provided in the summary. That omission limits interpretation of whether nonoperative management traded immediate surgical avoidance for delayed rebleeding or recurrent ED utilization. This is a crucial question for any hemostatic strategy in PTH, and the full text would need to be examined carefully to determine whether recurrence outcomes support the apparent early benefit.
Clinical Interpretation
This study sits at the intersection of emergency care, otolaryngology, and implementation science. Its main message is not simply that nebulized TXA may work, but that a thoughtfully designed institutional pathway can make a promising therapy reliably available at the point of care. In modern hospitals, this is often the harder problem.
The reduction in operative intervention is biologically plausible. Post-tonsillectomy bleeding frequently reflects local fibrinolysis and unstable clot formation in the healing tonsillar bed. A topical or locally delivered antifibrinolytic could therefore help stabilize a friable surface clot, reduce oozing, and buy time for observation and definitive ENT assessment. Nebulization also offers practical advantages over gargles or direct topical application in distressed patients, particularly children or adults with gagging, pain, or limited cooperation.
Equally important, the protocol maintained clear exclusions for severe bleeding and airway risk. This suggests that the observed reduction in OR use was not driven by delaying needed surgery in unstable patients, but by improving medical management in lower-acuity presentations. For clinicians, that distinction is central. Nebulized TXA should be viewed as an adjunct within a risk-stratified pathway, not a blanket substitute for operative control.
The order set utilization rate of 95.7% also deserves attention because it highlights the value of embedding clinical innovation into electronic workflow. In many institutions, uptake of new practices is undermined by logistical friction: uncertain dosing, formulary confusion, or variability between emergency physicians and consulting specialists. Here, the guideline appears to have resolved those barriers effectively.
Strengths of the Study
The study has several practical strengths. First, it addresses a common real-world problem in a high-stakes, time-sensitive setting. Second, it includes a sizable denominator of tonsillectomy procedures across two multi-year periods, allowing event rates to be contextualized. Third, it evaluates both implementation measures and clinical outcomes, which is especially useful when the intervention is a systems-level change rather than a single drug comparison. Fourth, the treatment pathway is clinically reproducible: the inclusion criteria are understandable, the exclusion criteria are sensible, and the use of an order set is transferable to other hospitals.
Limitations and Cautions
Despite the encouraging findings, this was not a randomized controlled trial. The pre-post design is vulnerable to secular trends, changes in surgical technique, evolving thresholds for operative intervention, differences in on-call otolaryngology practice, and broader changes in perioperative or ED management over time. The post-implementation period also included many more tonsillectomies than the pre-implementation period, which may reflect institutional growth or other system changes that could influence case mix or management patterns.
The abstract does not provide granular data on bleeding severity, timing of hemorrhage, TXA dosing details, concurrent interventions, or balancing measures such as admission rates, transfusion, aspiration events, or thromboembolic complications. Safety is especially relevant with any antifibrinolytic, even though nebulized delivery is generally presumed to have low systemic exposure. Likewise, recurrence outcomes are essential. A lower initial OR rate is reassuring only if delayed bleeding does not offset the benefit.
Generalizability may also be limited. This was a single-institution guideline implementation effort, and success may have depended on local culture, ENT-ED collaboration, formulary access, and electronic order infrastructure. Centers without these supports might reproduce the medication intervention but not the same level of protocol fidelity or clinical effect.
How This Fits With Existing Practice
Current tonsillectomy practice guidelines emphasize recognition of post-tonsillectomy hemorrhage as a potentially urgent complication, but they do not yet offer robust, high-level recommendations for nebulized TXA pathways. That is not surprising; evidence for this specific application remains largely observational. Even so, the present study adds meaningful support to a growing bedside practice pattern in which TXA is being used as a temporizing or stabilizing therapy for mucosal bleeding in the upper airway and oropharynx.
For emergency departments and otolaryngology services, the practical takeaway is that standardization may matter as much as the drug itself. A protocol that defines who should receive TXA, who should bypass it, how many treatments to give, and how to order the medication can reduce hesitation and improve treatment consistency. In implementation terms, this study suggests that reliability can be designed.
Practical Implications for Hospitals
Hospitals considering a similar pathway should focus on four components. First, create a shared ED-ENT algorithm that begins with airway and hemorrhage severity assessment. Second, define clear inclusion criteria, such as active bleeding or visible clot without immediate airway compromise. Third, build a simple order set that includes medication, nursing instructions, monitoring, and automatic consultation prompts. Fourth, track balancing measures prospectively, including repeat bleeding, admission, OR transfer after initial observation, and adverse events.
Because the intervention is relatively low complexity, this is a plausible candidate for multicenter collaborative study. A stepped-wedge or pragmatic cluster-randomized design could help separate the effect of TXA from the effect of concurrent practice change. Standardized outcomes should include not just initial OR avoidance, but rebleeding within 24 to 72 hours, readmission, transfusion, and patient-centered outcomes such as discomfort and length of stay.
Conclusion
Lavin and colleagues provide an instructive example of how a clinical care guideline can translate an emerging therapy into everyday emergency and otolaryngology practice. In their pre-post analysis, standardized use of nebulized TXA for selected patients with post-tonsillectomy hemorrhage achieved high protocol adherence and was associated with a notable reduction in returns to the operating room.
The findings are clinically promising and operationally important. At the same time, they should be interpreted as strong implementation-based observational evidence rather than definitive proof of treatment efficacy. For now, the study supports nebulized TXA as a pragmatic, low-barrier adjunct in a risk-stratified PTH pathway, while reinforcing the need for prospective comparative studies that address recurrence, safety, and multicenter generalizability.
Funding and Trial Registration
The abstract does not report funding information or a ClinicalTrials.gov registration number. This is consistent with a quality-improvement implementation study but should be confirmed in the full publication.
Citation and Selected References
Lavin J, Billings K, Smith A, Patel K, Corboy J, Hazkani I. Clinical Care Guideline Implementation of Nebulized Tranexamic Acid in Post-Tonsillectomy Hemorrhage. The Laryngoscope. 2026-05-29. PMID: 42212485.
Mitchell RB, Archer SM, Ishman SL, et al. Clinical Practice Guideline: Tonsillectomy in Children (Update). Otolaryngology-Head and Neck Surgery. 2019;160(1_suppl):S1-S42.
